Isert L, Passi M, Freystetter B, Grab M, Roidl A, Muller C
Mater Today Bio. 2025; 30:101401.
PMID: 39759848
PMC: 11699613.
DOI: 10.1016/j.mtbio.2024.101401.
Huang Z, Haider Q, Sabir Z, Arshad M, Siddiqui B, Alam M
Sci Rep. 2023; 13(1):22756.
PMID: 38123636
PMC: 10733363.
DOI: 10.1038/s41598-023-50045-z.
Alves L, Meira D, Merigueti L, Casotti M, do Prado Ventorim D, Ferreira Figueiredo Almeida J
Genes (Basel). 2023; 14(7).
PMID: 37510269
PMC: 10378988.
DOI: 10.3390/genes14071364.
Azadeh M, Salehzadeh A, Ghaedi K, Sasani S
Adv Biomed Res. 2023; 12:120.
PMID: 37434942
PMC: 10331528.
DOI: 10.4103/abr.abr_200_22.
Daniluk K, Lange A, Wojcik B, Zawadzka K, Balaban J, Kutwin M
Int J Mol Sci. 2023; 24(9).
PMID: 37176095
PMC: 10179033.
DOI: 10.3390/ijms24098388.
An In Vitro Approach to Model EMT in Breast Cancer.
Isert L, Mehta A, Loiudice G, Oliva A, Roidl A, Merkel O
Int J Mol Sci. 2023; 24(9).
PMID: 37175467
PMC: 10177865.
DOI: 10.3390/ijms24097757.
Intra- and Peritumoral Radiomics Model Based on Early DCE-MRI for Preoperative Prediction of Molecular Subtypes in Invasive Ductal Breast Carcinoma: A Multitask Machine Learning Study.
Zhang S, Wang X, Yang Z, Zhu Y, Zhao N, Li Y
Front Oncol. 2022; 12:905551.
PMID: 35814460
PMC: 9263840.
DOI: 10.3389/fonc.2022.905551.
Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures.
Kashyap D, Pal D, Sharma R, Garg V, Goel N, Koundal D
Biomed Res Int. 2022; 2022:9605439.
PMID: 35480139
PMC: 9038417.
DOI: 10.1155/2022/9605439.
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit N, Ding K
Nat Commun. 2022; 13(1):2011.
PMID: 35440136
PMC: 9019037.
DOI: 10.1038/s41467-022-29498-9.
Amino acid transporters as emerging therapeutic targets in cancer.
Saito Y, Soga T
Cancer Sci. 2021; 112(8):2958-2965.
PMID: 34091991
PMC: 8353895.
DOI: 10.1111/cas.15006.
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
Gorlov I, Orlow I, Ringelberg C, Hernando E, Ernstoff M, Cheng C
Melanoma Res. 2018; 28(5):380-389.
PMID: 29975213
PMC: 6448582.
DOI: 10.1097/CMR.0000000000000473.
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.
De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M
Oncotarget. 2018; 8(68):112816-112824.
PMID: 29348868
PMC: 5762553.
DOI: 10.18632/oncotarget.22643.
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Yuan Y, Kos F, He T, Yin H, Li M, Hardwick N
Oncoimmunology. 2017; 6(12):e1363138.
PMID: 29209571
PMC: 5706612.
DOI: 10.1080/2162402X.2017.1363138.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Fragomeni S, Sciallis A, Jeruss J
Surg Oncol Clin N Am. 2017; 27(1):95-120.
PMID: 29132568
PMC: 5715810.
DOI: 10.1016/j.soc.2017.08.005.
Epigenetics and Precision Oncology.
Werner R, Kelly A, Issa J
Cancer J. 2017; 23(5):262-269.
PMID: 28926426
PMC: 5708865.
DOI: 10.1097/PPO.0000000000000281.
Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure.
Verheuvel N, Voogd A, Tjan-Heijnen V, Siesling S, Roumen R
Breast Cancer Res Treat. 2017; 165(3):555-563.
PMID: 28656490
PMC: 5602026.
DOI: 10.1007/s10549-017-4342-1.
Quantitative prediction of oral cancer risk in patients with oral leukoplakia.
Liu Y, Li Y, Fu Y, Liu T, Liu X, Zhang X
Oncotarget. 2017; 8(28):46057-46064.
PMID: 28545021
PMC: 5542248.
DOI: 10.18632/oncotarget.17550.
Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.
Mendes T, Kluskens L, Rodrigues L
Adv Sci (Weinh). 2016; 2(11):1500053.
PMID: 27980912
PMC: 5115335.
DOI: 10.1002/advs.201500053.
A new ten-gene risk fraction model serving as prognostic indicator for clinical outcome of multiple myeloma.
Hu A, Huang Z, Liu P, Xiang T, Yan S, Zhang L
Tumour Biol. 2016; 37:15967–15975.
PMID: 27709552
DOI: 10.1007/s13277-016-5449-4.
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Stavridi F, Kalogeras K, Pliarchopoulou K, Wirtz R, Alexopoulou Z, Zagouri F
PLoS One. 2016; 11(10):e0164013.
PMID: 27695115
PMC: 5047528.
DOI: 10.1371/journal.pone.0164013.